Relmada Therapeutics Q3 2026 Earnings Date & Estimates

Relmada Therapeutics (NASDAQ:RLMD) is a clinical-stage biotechnology company focused on developing therapies for central nervous system disorders, particularly major depressive disorder and other conditions associated with significant unmet medical needs. The company is headquartered in the United States and conducts its research and clinical development activities through collaborations and trials involving patients and research sites in multiple regions.

Relmada’s lead product candidate is REL-1017, also known as esmethadone or dextromethadone. It is an investigational, orally administered N-methyl-D-aspartate (NMDA) receptor antagonist being studied as a potential treatment for major depressive disorder, including use as an adjunctive therapy for patients who do not respond adequately to standard antidepressants. REL-1017 is not approved for commercial use, and its safety and effectiveness remain subject to clinical and regulatory evaluation.

The company’s development strategy has centered on advancing novel neuroscience medicines through clinical testing and seeking regulatory approval for potential commercialization. Relmada Therapeutics has been associated with Sergio Traversa, who has served as its chief executive officer and has played a leading role in the company’s development efforts.